Long-COVID / post-viral
The one rigorously-trialed peptide (aviptadil) failed; prioritize plausibility + safety.
Decision support, not prescription. You decide.
Warning — BPC-157 crash risk in post-viral/ME-CFS
Post-viral/ME-CFS patients report crashing at standard dose; microdose 10–25%.
Candidate agents
3 agents · tap to expand▶Thymosin Alpha-1LeadEmergingThymosin alpha-1 has arguably the most mechanistically coherent rationale on this list for long-COVID, but there is no direct long-COVID data at all and the human evidence that exists comes entirely from acute COVID and is internally conflicting; treat it as a rational hypothesis, not an established or even emerging therapy for this condition.expand
Thymosin alpha-1 has arguably the most mechanistically coherent rationale on this list for long-COVID, but there is no direct long-COVID data at all and the human evidence that exists comes entirely from acute COVID and is internally conflicting; treat it as a rational hypothesis, not an established or even emerging therapy for this condition.
▸Full clinical story
The specific long-COVID rationale is T-cell exhaustion and immune dysregulation: severe COVID features lymphopenia and exhausted, PD-1/Tim-3-high CD8+ T cells, and thymosin alpha-1 promotes thymic output and can reverse that exhaustion phenotype. Because persistent T-cell exhaustion and immune dysregulation are among the leading proposed drivers of long-COVID, the mechanism transfers more plausibly here than for most peptides, but this remains a mechanistic hypothesis that has never been tested in post-viral patients.
Grade preclinical for this condition: the rationale rests on mechanism plus indirect acute-COVID data, with zero long-COVID studies. A retrospective severe-COVID series reported lower mortality with thymosin (11.11% vs 30.00%) alongside restored T-cell counts and reduced T-cell exhaustion markers, and a 2023 meta-analysis of 8 studies found reduced mortality (RR 0.59, 95% CI 0.37-0.93; I2=84%, high heterogeneity). But a 771-patient multicenter retrospective study found the apparent mortality benefit disappeared after propensity matching (51.0% vs 52.9%, no significant difference), so even the acute-COVID signal is unconfirmed and heavily confounded by indication. None of this is evidence in long-COVID, where no trial or cohort exists.
Anecdotal community signal only, not evidence: thymosin alpha-1 (often subcutaneous, sometimes cycled with thymosin beta-4/TB-500) is one of the more commonly reported peptides among long-COVID patients seeking an immune 'reset,' with scattered self-reports of improved fatigue and fewer infections. These are uncontrolled anecdotes, frequently confounded by concurrent interventions and spontaneous recovery, and demonstrate no efficacy.
Context, not a protocol: acute-COVID studies used ~1.6 mg subcutaneously once or twice daily. Community long-COVID use tends toward lower intermittent dosing (e.g. ~1.5 mg a few times weekly in cycles), which has no trial basis whatsoever.
As an immune modulator it is theoretically double-edged in a condition where both immune exhaustion and autoimmunity/hyperinflammation are proposed drivers: stimulating T-cell activity could plausibly help some phenotypes and aggravate others, and it has not been characterized in autoimmune-predominant long-COVID. Product quality is a real hazard given heavy reliance on compounded/gray-market sources, and the acute-COVID data are too confounded to extrapolate either efficacy or safety.
Best biological rationale of the mapped agents for long-COVID, but no direct evidence in the condition and conflicting acute-COVID data that weakens to null after adjustment. A defensible candidate for formal trials and, at most, for cautious fully-consented individualized use, but it must not be presented to patients as proven or even as having emerging clinical support in long-COVID.
- Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. ↗
- The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression. ↗
- The effect of thymosin α1 on mortality of critical COVID-19 patients: A multicenter retrospective study. ↗
- Positive8 corroboratinganecdotal
Dose: 500mcg · subq · 2x weekly
Strongest LC reports: fatigue/brain-fog resolution; effect lasts 48-72h
Side effects: flu-like first-dose reaction
transientr/covidlonghaulers
No peer data yet. Aggregates appear once ≥3 clinicians log an outcome.
▶VIPNoneVasoactive intestinal peptide (as the drug aviptadil) is the one member of this list that was actually put through a rigorous COVID trial and failed; for long-COVID specifically it is untested and should be treated as unproven.expand
Vasoactive intestinal peptide (as the drug aviptadil) is the one member of this list that was actually put through a rigorous COVID trial and failed; for long-COVID specifically it is untested and should be treated as unproven.
▸Full clinical story
VIP is concentrated in the lung and acts on type II alveolar cells and immune cells to blunt cytokine release and protect surfactant, which is why it was pursued for acute COVID lung injury; the extension to long-COVID is purely speculative, resting on generic anti-inflammatory and vasodilatory effects rather than any demonstrated post-viral mechanism.
Grade none for this condition. The pivotal randomized, placebo-controlled TESICO trial in acute COVID hypoxaemic respiratory failure showed no benefit on the day-90 ordinal outcome (OR 1.11, 95% CI 0.80-1.55; p=0.54) and no mortality benefit (38% vs 36%; HR 1.04, 95% CI 0.77-1.41), and the aviptadil arm was stopped for futility. There are no trials, cohorts, or case series of VIP/aviptadil in long-COVID at all.
Anecdotal community signal only, not evidence: intranasal VIP is discussed in some patient and biohacker circles for post-viral and 'CIRS'-type symptoms, and a handful of long-COVID patients report trying compounded nasal VIP. This is uncontrolled self-report with no supporting data and no demonstrated efficacy; it should not be read as evidence of benefit of any kind.
Context, not a protocol: the failed IV aviptadil regimen escalated to roughly 600/1200/1800 pmol/kg over three days (12-h daily infusions). Community intranasal use (e.g. 50 mcg sprays) is entirely separate, unstandardized, and unvalidated.
IV aviptadil causes hypotension, diarrhea, and infusion reactions from systemic vasodilation; it should not be positioned as a benign 'peptide' option. Given a clean negative RCT in the closest tested population, spending patient time and money here diverts from better-supported supportive care for long-COVID.
This is a known negative in acute COVID and a blank slate in long-COVID. Absent any post-viral data, VIP does not warrant clinical use for long-COVID; the honest position is 'tried in COVID, failed, never studied in long-COVID.'
▶BPC-157⚠ cautionPromotes angiogenesisexpand
Warning — BPC-157 crash risk in post-viral/ME-CFS
▸Evidence, community & peer detail
No evidence rows yet.
- Mixed4 corroboratinganecdotal
Dose: 200mcg · subq · daily
~10% baseline lift; crash risk in severe ME/CFS
Side effects: crash, anhedonia concern
crash microdoser/covidlonghaulers
No peer data yet. Aggregates appear once ≥3 clinicians log an outcome.
Matching protocol templates
Browse all →Neuroimmune balance and fatigue recovery
Immune recalibration and systemic recovery
Immune reset, energy restoration, and cytokine balance in autoimmune or fatigue syndromes
The platform surfaces evidence, community signal and peer outcomes with enforced cautions. It never decides treatment — the licensed clinician orders labs, writes notes, and prescribes.